Program Overview

Tradition of Excellence

Patients and their families are at the center of our program. Each individual is treated with respect, dignity, and compassion. Having the patient at the top of the treatment pyramid enables the Blood and Marrow Transplant Program at Northside Hospital (NH-BMT) team to deliver outstanding clinical care with excellent patient satisfaction.

The Center for International Blood and Marrow Transplant Research (CIBMTR) and the National Marrow Donor Program (NMDP) have released the 2023 survival outcomes for related and unrelated allogeneic blood and marrow transplants. For fifteen consecutive years, 2009–2023, NH-BMT’s commitment to quality patient care has resulted in the program achieving survival outcomes that significantly exceed the expected range in related and unrelated allogeneic donor transplants1. There were 175 adult and pediatric transplant centers included in the analysis2.   Please visit bethematch.org/tcdirectory/index/60 to find additional information on understanding blood and marrow transplant survival outcome results.

Our program’s commitment to providing patients access to cutting-edge clinical research trials is demonstrated by NH-BMT being selected as a Core Clinical Center for the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) from July 2011 to July 2024.

NH-BMT staff members include nationally recognized physicians, advanced practice providers, nurses, coordinators, clinical BMT PharmD’s, a dedicated health psychologist, nutritionists, social worker, physical therapists and ancillary specialists.

Types of Transplants Performed

The NH-BMT program is one of the largest clinical transplant programs in the United States, serving patients undergoing blood and bone marrow transplants, primary leukemia treatment, and immunotherapy (CAR T-cell).

Physician coverage:

• Our program does not employ interns, residents or physicians in fellowship training - Physician Bio’s.

• A BMTGA physician is on call 24 hours a day, 7 days a week.

• Call 404.255.1930 to refer/speak with a physician.

The types of transplants performed are:

• Autologous Stem Cell Transplants

• Related and Unrelated Allogeneic Stem Cell Transplants

• Haploidentical Stem Cell Transplants

• Cord Blood Transplants

• Nonmyeloablative / Reduced Intensity Stem Cell Transplants

Comprehensive Inpatient and Outpatient Autologous and Allogeneic Transplant Program

We are committed to providing patients and their caregivers a comprehensive pathway to successful outcomes. While Northside has pioneered successful outpatient transplants, we are able to provide patients with the option to also have an inpatient autologous or allogeneic transplant.

At the New Patient Consult and Pre-BMT Evaluation, the NH-BMT team will meet with each patient and family member(s) to determine if an inpatient or outpatient transplant would be the best treatment or location option. We realize that for some patients, receiving an outpatient transplant is not feasible due to a lack of adequate caregiver support, transportation, local housing requirements, or financial considerations. The NH-BMT team works with each patient and their unique personal situation to determine the best location to have their transplant.

Nationally, NH-BMT has been a leader in the field of hematopoietic blood and marrow transplant by perfecting autologous and allogeneic transplants in the outpatient setting. BMTGA physician, Dr. Scott Solomon, wrote a peer-reviewed article, Outpatient Myeloablative Allo-SCT: A comprehensive approach yields decrease hospital utilization and low TRM. Bone Marrow Transplantation 2010 March;45(3):468-75., which demonstrated that receiving mobilization of stem cells, high-dose chemotherapy/total body irradiation, and post-transplant follow-up care in the outpatient setting is safe with outstanding outcomes www.marrow.org and excellent patient satisfaction.

If you receive your transplant in an inpatient or outpatient setting, you will receive the same outstanding care from our dedicated NH-BMT interdisciplinary team.

1. For the fourteenth consecutive year (2009–2022), NH-BMT achieved survival outcomes that significantly exceeded the expected range, as reported in the Center for International Blood and Marrow Transplant Research's Final December 2022 Transplant Center Survival Report and from reported outcome data from Be The Match®.
2. There were 175 adult and pediatric transplant centers included in the analysis. The survival information includes only patients who received their first allogeneic transplant between January 1, 2018, and December 31, 2020, and who reported follow-up. Specific transplant center information can be found at bethematch.org.